CellSeed Europe

Company snapshot

CellSeed Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Osteoarthritis of the Knee. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CellSeed Europe. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CellSeed Europe.

1. May 26, 2026 Clinical update

   CLS2901C (human [allogeneic] chondrocyte sheets) — Phase 3

View all clinical trial activity →

• What is CellSeed Europe?

  CellSeed Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Osteoarthritis of the Knee. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USP

• Is CellSeed Europe publicly traded?

  CellSeed Europe appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CellSeed Europe develop or market?

  We link 1 drug profile(s) where CellSeed Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cellseed-europe-ltd#company-drugs.

• What are the latest developments for CellSeed Europe?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CellSeed Europe focus on?

  CellSeed Europe focuses on Osteoarthritis of the Knee based on our analysis of their pipeline programs and drug development activities.